TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA granted accelerated approval to Voceryq, a plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis (RRP), to reduce the frequency of surgical removal of airway growths. In a 32-patient trial, 27% of a subgroup with at least three prior-year surgeries had no excisions during 12 months of follow-up. Postmarketing trials are required to verify the treatment’s clinical benefit.
The U.S. Food and Drug Administration has granted accelerated approval to Voceryq, a plasmid DNA-based immunotherapy intended to reduce the frequency of surgeries for adults with recurrent respiratory papillomatosis (RRP), a rare condition that causes wart-like growths in the airways. The decision makes the treatment an additional medical option for a disease commonly managed through repeated removal of the growths.
The FDA based its decision on efficacy data from RRP-001, an open-label phase I/II trial involving 32 patients who had undergone at least two surgeries in the year before enrollment. Among the 26 participants who had at least three surgeries in that period, seven—27%—had a complete response, defined as needing no surgical excisions during 12 months of follow-up. That result applies to this subgroup, not all trial participants.
Voceryq, whose generic name is doruxapapogene ralaplasmid-lalikinogene sifuplasmid, contains two plasmids with genetic instructions for HPV proteins and interleukin 12. According to the report, patients’ healthy cells use those instructions to prompt immune activity against cells infected with HPV types 6 and 11, which cause RRP. Treatment begins with surgical removal of visible growths, followed by four intramuscular doses given every three weeks.
The treatment is approved for use with the CELLECTRA 5PSP DNA medicine delivery device. The FDA’s accelerated approval pathway requires postmarketing trials to verify and describe the therapy’s clinical benefit. The label warns of possible muscle contractions, temporary bleeding and vasovagal reactions. Common adverse events reported in trials included injection-site reactions, headache, fatigue, high blood pressure, nausea and dizziness.
A Medical Option Beyond Repeat Surgery
RRP growths can return after removal, leaving some patients facing repeated procedures. The condition is caused by human papillomavirus and affects the respiratory tract, particularly the area around the larynx; severe disease can spread through the airways and make breathing difficult. There is no cure, according to the report, and surgery remains a way to remove recurring growths.
Repeated excisions can carry risks, including laryngeal injury, according to Simon Best, a trial investigator at Johns Hopkins University, in a statement issued by manufacturer Inovio Pharmaceuticals. The trial’s response measure—going a year without another excision—offers a relevant indicator for patients who have needed frequent procedures. But the reported result does not establish that every patient will avoid surgery, or that the therapy eliminates the disease.
Voceryq is also not the first medical treatment approved for RRP. The FDA approved zopapogene imadenovec (Papzimeos) for the condition in 2025, the report says. Voceryq’s approval adds another treatment approach while postmarketing studies are still needed to confirm its benefit.
Products Worth Considering
LEVOIT Vital 200S-P Smart Air Purifier for Large Rooms
Hyperice Normatec 3 Leg Compression Boots – Full Leg Recovery, Standard Size
Oral-B iO5 Rechargeable Electric Toothbrush with 5 Cleaning Modes
As an affiliate, we earn on qualifying purchases.
How the Trial Supported Approval
RRP is characterized by recurrent papillomas in the airways, with HPV types 6 and 11 identified as the causes in the source report. Growths can recur after surgery, so care may involve repeated procedures to remove them. The disease is rare, and the trial used for this FDA decision enrolled adults with a history of multiple operations in the preceding year.
The evidence came from an open-label phase I/II study, meaning participants and researchers knew the treatment being given. Its 32 participants had at least two prior-year surgeries; the 27% complete-response figure was reported only for the subgroup of 26 who had at least three. The FDA granted accelerated approval based on these efficacy data and requires further trials after approval.
“The approval of Voceryq is an important step in improving the quality of life for RRP patients as every surgery carries the risk of laryngeal injury.”
— Simon Best, MD, Johns Hopkins University investigator, in a statement from Inovio Pharmaceuticals
Questions Awaiting Postapproval Data
The trial was small and open-label, and the reported complete-response result covers a 26-person subgroup rather than everyone treated. The supplied report does not provide a comparison group, longer-term outcomes, or enough detail to determine how durable responses may be beyond the 12-month follow-up period. It also does not establish which patients are most likely to benefit.
The FDA’s accelerated approval means clinical benefit must still be verified in postmarketing trials. Details about those studies, including their design, timing and expected results, are not included in the source material. It is also not yet clear how Voceryq will compare with other treatment approaches in routine care.
Postmarketing Trials Must Verify Benefit
Inovio Pharmaceuticals and the FDA will need to follow the required postmarketing trials, which are intended to verify and describe Voceryq’s clinical benefit. The source report does not give a timetable for those studies or say when additional results are expected.
For now, the approved regimen begins with surgical debulking and continues with four doses at three-week intervals, used alongside the specified delivery device. Further trial results should help clarify the duration of response, safety profile and range of patients who may benefit. Until then, the 27% complete-response finding should be understood within the limits of the trial and subgroup reported.
Key Questions
What is Voceryq approved to do?
The FDA granted accelerated approval to Voceryq to reduce the frequency of surgical papilloma excisions in adults with recurrent respiratory papillomatosis. The approval does not establish that the treatment cures RRP.
How well did the therapy work in the trial?
Among 26 participants who had at least three surgeries in the year before treatment, 27% had no surgical excisions during 12 months of follow-up. The source does not report that figure for all 32 participants.
How is Voceryq given?
Treatment starts with surgical removal of visible papilloma, followed by an intramuscular dose every three weeks for four doses. It is used with the CELLECTRA 5PSP delivery device.
What side effects were reported?
Common adverse events in trials included injection-site reactions, headache, fatigue, hypertension, nausea and dizziness. The label also warns of possible muscle contractions, transient bleeding and vasovagal reactions.
Is the treatment’s benefit fully established?
No. The FDA granted accelerated approval based on the reported trial data and requires postmarketing trials to verify and describe clinical benefit. The source does not provide a schedule for those studies.
Source: medpagetoday.com
